A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2006
10/31/2006	US7129211 Adipocyte Insulin adpinsl with Insulin A and B chains and an effective method of treating type 2 diabetes in a subject using adipocyte insulin
10/31/2006	US7129210 cross-linkable protein in the form of a solution or suspension; cross-linking agent solution includes an aldehyde and an amino acid containing species reactive with the aldehyde
10/31/2006	US7129208 Synthetic ion channels
10/31/2006	US7129207 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders
10/31/2006	US7129203 Deleting at least one amino acid residue on the protein, and contacting the protein with polyethylene glycol under conditions sufficient to conjugate the polyethylene glycol to the protein
10/31/2006	US7129085 Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
10/31/2006	US7129078 DNA encoding androgen receptor fragment
10/31/2006	US7129077 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder
10/31/2006	US7129074 Nucleoside triphosphate diphosphohydrolase (NTPDase 8) and uses thereof
10/31/2006	US7129064 Canine hepatocyte growth factor
10/31/2006	US7129061 Pure polypeptide containing a fragment capable of binding to and inducing apoptosis in a carcinoma cell; Tumor Necrosis Factor Related ligand or "TRELL", a polypeptide which is a member of the Tumor Necrosis Factor Family
10/31/2006	US7129052 Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins
10/31/2006	US7129040 identification, on human chromosome 10, of a tumor suppressor gene. Defects in this gene are associated with the development of cancers, such as gliomas
10/31/2006	US7129039 Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
10/31/2006	US7129034 Culturing stem cell with fibroblast growth factor and epidermal growth factor
10/31/2006	US7128930 Topically administering to the genitals of a patient with sexual dysfunction an ethyl ester of L-arginine, combination of ascorbic acid and ascorbic acid palmitate as antioxidants to cause the desired level of blood flow to erectile tissue while minimizing peroxynitrite levels
10/31/2006	US7128923 Mixture with non-formaldehyde preservative; microbiocides; chemical resistance; drugs, medical equipment, cosmetics; antiaging, wrinkle resistance; skin disorders
10/31/2006	US7128922 Compositions of leukaemia inhibitory factor
10/31/2006	US7128912 Fibronectin binding protein compositions and methods of use
10/31/2006	US7128911 Virus-like particle, and an antigen or antigenic determinant of a receptor activator factor kappa beta ligand protein, fragment or peptide
10/31/2006	US7128908 Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
10/31/2006	US7128907 Methods of treating crohn's disease with anti-TNF antibodies
10/31/2006	US7128906 T1 receptor-like ligand II and uses thereof
10/31/2006	US7128905 methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
10/31/2006	US7128904 Material containing metal ion ligand complex producing nitric oxide in contact with blood
10/31/2006	US7128896 using carbocyanine dyes; photodynamic therapy; in vivo supplying to tumor
10/31/2006	CA2372688C Device and method for infusion of small molecule insulin mimetic materials
10/31/2006	CA2333405C Spill resistant pharmaceutical compositions
10/31/2006	CA2332183C Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (egf-r); diagnostic and therapeutic use
10/31/2006	CA2293819C A method for in vitro molecular evolution of protein function
10/31/2006	CA2281474C Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof
10/31/2006	CA2243755C Streptococcal c5a peptidase vaccine
10/31/2006	CA2230672C Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
10/31/2006	CA2212649C Hydrolyzed collagen type ii and use thereof
10/31/2006	CA2172350C Preparation of autologous plasma and fibrin gel
10/31/2006	CA2157376C Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
10/31/2006	CA2136953C A method for using lipoprotein associated coagulation inhibitor to treat sepsis
10/31/2006	CA2136751C Salts of peptides with carboxy-terminated polyesters
10/31/2006	CA2129733C Mammalian expression systems for hcv proteins
10/26/2006	WO2006113898A2 Pif tetrapeptides
10/26/2006	WO2006113841A2 Nucleic acid-like proteins
10/26/2006	WO2006113796A2 Microbial cellulose materials for use in transdermal drug delivery system
10/26/2006	WO2006113681A2 Plant-derived elastin binding protein ligands and methods of using the same
10/26/2006	WO2006113667A1 Therapeutic peptides for the treatment of metastatic cancer
10/26/2006	WO2006113666A2 Amphiphilic polymers and methods of use thereof
10/26/2006	WO2006113623A2 Elimination of heterogeneous or mixed cell population in tumors
10/26/2006	WO2006113540A2 Use of ntrosylated hemoglobin
10/26/2006	WO2006113487A1 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
10/26/2006	WO2006113452A2 Glycoprotein hormone analogs
10/26/2006	WO2006113429A2 Viral inhibitors
10/26/2006	WO2006113331A1 Methods for treating and preventing fibrosis by il-21 / il-21r antagonists
10/26/2006	WO2006113311A2 Compositions and uses of a galectin for treatment of dry eye syndrome
10/26/2006	WO2006113210A2 Diagnostic multimarker serological profiling
10/26/2006	WO2006112930A2 Q3 sparc deletion mutant and uses thereof
10/26/2006	WO2006112739A1 Novel peptides and methods for the treatment of inflammatory disorders
10/26/2006	WO2006112738A1 Novel peptides and methods for the treatment of inflammatory disorders
10/26/2006	WO2006112737A1 Vesiculins
10/26/2006	WO2006112551A2 A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS
10/26/2006	WO2006112550A2 A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS
10/26/2006	WO2006112451A1 Anti-cancer agent comprising protein c inhibitor
10/26/2006	WO2006112441A1 Anti-hepatitis c virus agent containing bmp-7
10/26/2006	WO2006112012A1 Nutrient composition
10/26/2006	WO2006111946A2 Toll-like receptor 14 (tlr14 ) and use thereof
10/26/2006	WO2006111745A2 Composition and method for treating viral infection
10/26/2006	WO2006111720A2 Use
10/26/2006	WO2006111616A1 Peptide vaccine for influenza virus
10/26/2006	WO2006111596A1 Use of hdac6 protein tubulin deacetylase activity agonist compounds in the preparation of pharmaceutical compositions, said pharmaceutical compositions and applications of same in the treatment of viral infections
10/26/2006	WO2006111424A1 Methods for identifying modulators of cb1 and cb2 cannabinoid receptors and their use in wound healing
10/26/2006	WO2006111355A1 Compositions for the prevention and the treatment of pain comprising phosphatidylethanolamine-binding protein (pebp) derived molecules
10/26/2006	WO2006111169A1 Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
10/26/2006	WO2006111103A1 Functions and uses of gpr39 gene in mammalian central nervous system
10/26/2006	WO2006111060A1 A method for isolating and purifying immuno-modulating polypeptide from cow placenta
10/26/2006	WO2006093405A3 Means and methods for producing polymers comprising peptide in a side chain
10/26/2006	WO2006087340A3 Highly potent full and partial agonists and antagonists of the nociceptin/orphanin fq receptor
10/26/2006	WO2006084694A3 Use of the mcm8 gene for the preparation of a pharmaceutical composition
10/26/2006	WO2006077035A9 Peptides with neuropeptide-2 receptor (y2r) agonist activity
10/26/2006	WO2006066110A3 Cav2 RELATED COMPOSITIONS AND METHODS
10/26/2006	WO2006058539A3 Growth hormone secretagogue receptor 1a ligands
10/26/2006	WO2006045710A3 Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
10/26/2006	WO2006020244A3 Compositions and methods related to heart failure
10/26/2006	WO2006004696A3 Compositions and methods for the prevention and control of insulin-induced hypoglycemia
10/26/2006	WO2005099758A3 Injectable bioartificial tissue matrix
10/26/2006	WO2005079840A3 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
10/26/2006	WO2005074973A9 Method of inducing or modulating immune response
10/26/2006	WO2005067460A3 Epha2 vaccines
10/26/2006	WO2005060542A3 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
10/26/2006	WO2005056578A9 High-level expression of fusion polypeptides in plant seeds utilizing seed-storage proteins as fusion carriers
10/26/2006	WO2005041891A3 Neutrophil activation by immune response modifier compounds
10/26/2006	WO2004078995A3 Methods of modulating and of identifying agents that modulate intracellular calcium
10/26/2006	WO2004078147A3 Oxytocin controlled release formulations and methods of using same
10/26/2006	WO2004063153A3 Low efficacy gonadotropin agonists and antagonists
10/26/2006	WO2002101008A3 Intracellular signaling molecules
10/26/2006	WO2002100445A8 Treatment and composition for wound healing
10/26/2006	WO2002078420A3 Molecules for disease detection and treatment
10/26/2006	US20060242724 Receptor
10/26/2006	US20060242718 SOCS-box containing peptides
10/26/2006	US20060241290 recombinant or monoclonal antibodies comprising the antigen-binding fragments specific for polypeptides, used for treating the effects of stroke, hypoxia and/or ischemia
10/26/2006	US20060241286 Novel peptides and the application thereof in therapy
10/26/2006	US20060241284 Transmembrane protein amigo and uses thereof
10/26/2006	US20060241281 Peptidomimetic polymers for antifouling surfaces

1 ... 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 ... 3163